Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

JAM2 interacts with alpha4beta1. Facilitation by JAM3.

Sonia A Cunningham1, Jose M Rodriguez, M Pia Arrate

  • 1Department of Pharmacology, Texas Biotechnology Corporation, Houston, Texas 77030, USA. scunningham@tbc.com

The Journal of Biological Chemistry
|June 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated evaluation of antibody responses to mosquitoes and mosquito-borne pathogens using highly multiplexed serology.

Science advances·2026
Same author

Textbook outcome in surgery for primary hyperparathyroidism: first steps toward a composite quality metric.

Updates in surgery·2026
Same author

Modification of albendazole pharmacokinetics by menbutone administration in calves.

Frontiers in veterinary science·2026
Same author

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance.

bioRxiv : the preprint server for biology·2026
Same author

Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2026
Same author

PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Correction: Characterization of Mast2 kinase defines structural features, regulation, and substrates.

The Journal of biological chemistry·2026
Same journal

Isotope-Edited ESEEM: A New Method for Probing Copper Binding Sites in Neurodegenerative Proteins.

The Journal of biological chemistry·2026
Same journal

Introduction to the Thematic Review Series on Intracellular Protein Degradation. The ubiquitous biology of intracellular protein degradation: a tribute to Alfred L. ("Fred") Goldberg.

The Journal of biological chemistry·2026
Same journal

Correction: Aromatic residue-rich amino-terminal segments of temporin L self-assemble into collagen-mimetic peptides with cell-adhesion properties.

The Journal of biological chemistry·2026
Same journal

YhbO is a DJ-1 family glyoxalase and α-oxoaldehyde hydratase that confers resistance to reactive carbonyl stress (112).

The Journal of biological chemistry·2026
Same journal

ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB.

The Journal of biological chemistry·2026
See all related articles

Junctional adhesion molecule 2 (JAM2) binds T cells via JAM3, engaging alpha(4)beta(1) integrins. This interaction, crucial for T cell adhesion, can be targeted by drugs, offering therapeutic potential.

Area of Science:

  • Immunology
  • Cell Adhesion Biology
  • Molecular Interactions

Background:

  • Junctional adhesion molecule 2 (JAM2) mediates T cell adhesion through interactions with JAM3.
  • Integrin involvement in JAM2-mediated T cell adhesion was suggested by cation-dependent binding.

Purpose of the Study:

  • To elucidate the specific integrin interaction mediated by JAM2 on T cells.
  • To investigate the role of JAM3 in enabling JAM2-integrin engagement.
  • To explore the potential for therapeutic intervention targeting this adhesion pathway.

Main Methods:

  • Utilized neutralizing antibodies against integrins to identify specific interactions.
  • Employed alpha(4)-specific inhibitors (TBC 772) to assess drug intervention efficacy.
  • Investigated the necessity of JAM3 expression for JAM2-integrin binding.

Related Experiment Videos

  • Characterized the JAM2 Ig-like fold's role in binding JAM3 and alpha(4)beta(1) using mutagenesis.

    • Main Results:

    • Identified an interaction between JAM2 and the alpha(4)beta(1) integrin on T cells, enhanced by Mn(2+).
    • Demonstrated that TBC 772 significantly attenuates the Mn(2+)-enhanced JAM2 binding component.
    • Showed that JAM2 engagement with alpha(4)beta(1) requires prior JAM2-JAM3 adhesion and is abolished in JAM3-deficient cells.
    • Confirmed that JAM2's first Ig-like fold binds both JAM3 and alpha(4)beta(1), with Asp-82 mutation not affecting alpha(4)beta(1) binding.

    Conclusions:

    • JAM2 interacts with T cells via alpha(4)beta(1) integrins, a process contingent on prior JAM2-JAM3 binding.
    • This JAM2-JAM3-alpha(4)beta(1) axis represents a druggable target for modulating T cell adhesion.
    • JAM2 utilizes a distinct mechanism compared to other Ig superfamily members for integrin engagement.